news
Up to 10-fold increase in assay sensitivity – discover Morffi™ at MEDICA 2016
3 November 2016 | By BBI Solutions
BBI Solutions will be showcasing its Morffi™ signal enhancement technology on Stand F26 in Hall 1 at MEDICA 2016...
List view / Grid view
Immunotherapy
news
‘Game-changing’ immunotherapy doubles head and neck cancer survival
10 October 2016 | By Niamh Louise Marriott, Digital Content Producer
An immunotherapy drug has been hailed as a ‘game changer’ after being found to greatly improve survival for patients with relapsed head and neck cancer...
news
BBI Solutions launches innovative conjugate blocking technology that enhances signal intensity for lateral flow immunoassays
23 September 2016 | By BBI Solutions
BBI Solutions has launched Morffi™, a novel conjugate blocking technology that enhances signal intensity and improves the sensitivity of lateral flow immunoassays, at the Lateral Flow Test Development seminar in Seattle, USA, on the 20th September...
news
Cancer immunotherapy drugs linked to autoimmune diseases
24 June 2016 | By Victoria White, Digital Content Producer
Some cancer patients taking the immunotherapy drugs ipilimumab and nivolumab may be at a higher-than-normal risk of developing autoimmune diseases...
news
Chemo may boost immunotherapy power in ovarian cancer
15 June 2016 | By Victoria White, Digital Content Producer
A study has found that women with ovarian cancer may benefit more from immunotherapy drug treatments if they are given straight after chemotherapy...
news
Study describes extraordinarily potent mRNA cancer immunotherapy
2 June 2016 | By Victoria White, Digital Content Producer
BioNTech has announced the publication of a study that describes the first example of a clinically relevant and systemic mRNA cancer immunotherapy...
news
Positive interim review in ongoing AML WT1 T cell clinical trial
14 April 2016 | By Victoria White, Digital Content Producer
The Cell and Gene Therapy Catapult has announced a positive interim review of a Phase I/II trial using WT1-TCR t-cell therapy to target acute myeloid leukaemia...
news
Forecasting in dynamic Oncology Markets
14 March 2016 | By Black Swan Analysis
Two big things struck me as interesting during an Innovations in Oncology Conference in Edinburgh this month...
news
Researchers make cancer immunotherapy ‘breakthrough’
4 March 2016 | By Victoria White
Researchers have found the tools necessary to give immunotherapy the precision guidance that patients with cancer so desperately need...
article
Directing a weaponised attack on cancer with Natural Killer Receptor T-Cells
Natural killer receptor T-cells have the potential to become a real game changing treatment for patients with cancer. Here, Dr Frédéric Lehmann, VP Immuno-Oncology, Celyad, discusses this new cancer fighting technology...
whitepaper
Application Note: Multiparameter profiling of a Structure Activity Relationship (SAR) library for immunological activity in human PBMCs
We describe a no-wash, high throughput screen that provides a multiparametric activity profile for a structure activity relationship (SAR) library derived from immunomodulatory compounds...
news
Accelerate development of Cancer Immunotherapy (iOnc) drugs with new PathHunter® Checkpoint Assays from DiscoveRx
14 January 2016 | By DiscoveRx
DiscoveRx Corporation announced the expansion of its PathHunter cell-based assays portfolio with the release of PathHunter Checkpoint Assays...
news
Early immune effect of SCIB1 observed by ImmunTraCkeR diagnostic
11 January 2016 | By Victoria White
Cancer vaccine SCIB1 is a DNA ImmunoBody immunotherapy encoding a human IgG1 antibody, with three epitopes from gp100 and one from TRP-2 engineered into its CDR regions...
news
Novartis expands its cancer immunotherapy portfolio
21 October 2015 | By Victoria White
Novartis is broadening its portfolio of cancer immunotherapies through the acquisition of Admune Therapeutics and licensing agreements with Palobiofarma and XOMA Corporation...
whitepaper
Whitepaper: Multiplexed cancer immune response analysis nCounter® PanCancer Immune Profiling Panel for gene expression
The ability of mutated cells to give rise to pathological cancer relies upon the capability of these cells to evade immune recognition, suppress immune activity, and persist in a chronically inflamed environment. Tremendous growth in the understanding of these complex processes is beginning to generate breakthroughs in the treatment of…
